August 19, 2025
Editorial commentary: Understanding the cardiovascular benefits of glucagon-like peptide-1 (GLP-1) receptor agonists. Trends in Cardiovascular Medicine. 2024.
Over the last two decades the therapeutic options for management of type 2 diabetes and obesity have dramatically expanded. The mandated cardiovascular safety trials have uncovered further therapeutic benefits of glucagon-like peptide-1 receptor agonist. ...
August 18, 2025
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology. Trends Endocrinol Metab. 2025.
SGLT-2 inhibitors and GLP-1 receptor agonists, new medications that reduce the risk of heart disease in people with and without type 2 diabetes, may have a role to play in mitigating cardiovascular risk in type 1 diabetes. ...
